Catalyst Pharmaceuticals CCO Sells 74% of Holdings for ~$256,200
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Executive Sell-off: Catalyst Pharmaceuticals' Chief Commercial Officer Jeffrey Del Carmen exercised and sold 10,983 shares on November 26, 2025, for approximately $256,200, significantly reducing his direct holdings to 3,962 shares, indicating a cautious outlook on the company's future stock performance.
- Ownership Change: The 10,983 shares sold represented about 73.49% of Del Carmen's direct equity holdings, which materially decreases his stake and may affect market perceptions regarding executive confidence in the company.
- Historical Transaction Comparison: Since August 2024, Del Carmen has completed three sales, and while the current transaction size is smaller, the high percentage sold raises investor concerns, especially against the backdrop of the company's recent strong performance.
- Company Performance Context: Catalyst reported third-quarter revenues of $148.4 million, up 17.4% year-over-year, and raised its full-year 2025 revenue guidance, suggesting that despite the insider selling, the company's ongoing profitable growth momentum remains encouraging.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.290
Low
33.00
Averages
34.00
High
35.00
Current: 23.290
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
